**Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial**

Date

GP Address

Dear [name of GP]

|  |  |
| --- | --- |
| **Name of patient:** |  |
| **Date of Birth:** |  |

This is to inform you that the above patient registered under your care is participating in the Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) trial (REC ref. 21/EM/0246; CTA ref. 03057/0075/001-0001)

Consent has been obtained from the patient, or proxy consent has been obtained from their relative/carer both for their participation in the trial and to provide you with this information.

The trial aims to assess whether metoclopramide reduces mortality in patients with dysphagia after stroke, reduces pneumonia and improves neurological recovery at 14 days and improves long term outcomes at 6 months. It also aims to assess cost-effectiveness and cost-utility.

It is aimed that around 2,100 patients with stroke resulting in severe neurological impairment and dysphagia will be randomised into this trial.

I enclose a copy of the participant information sheet for your information.

We may contact you to check on the patient’s vital status prior to contacting them at 6 months.

If you need any more information or have any questions then please do not hesitate to contact your patient’s research team using the contact details below.

Yours sincerely,

Name: *insert name*  Job Title: *insert job title*

**RESEARCH TEAM CONTACT DETAILS**

*Add local research team contact details here*